Drug intelligence / Profile preview

KY0467

Development stage: Unknown
Lead developer: Jiangsu Kanion Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KY0467 is an investigational oral drug developed by Jiangsu Kanion Pharmaceutical. It is currently in Phase 2 clinical development, primarily targeting infectious diseases. The precise mechanism of action for KY0467 has not been disclosed publicly, and it is not known to represent a novel mechanism of action. Clinical trials have focused on evaluating the safety and tolerability of single and multiple oral doses in healthy adults under fasting conditions[1][2][3].

Beyond the preview

Go deeper on KY0467.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KY0467.

Explore the full profile